Figure 4
IFN-β is derived from activated hMSCs, following coculture with MDA cells. (a) Quantitative RT-PCR for IFN-β from hMSCs after coculture with MDA (MB-231) cells. Values are mean±S.D. for triplicate of the assay. (b) Real-time RT-PCR for IFN-β from hMSCs treated with apoptotic MDA (MB-231) cells (Apot cells). Apoptotic MDA cells were treated with either RNase (R) or DNase (D). Values are mean±S.D. for triplicate of the assay. (c) Quantitative RT-PCR for IFN-β from hMSCs treated with TNF-α and either poly(I:C) or poly(dA:dT) (1 μg/ml). Values are mean±S.D. for triplicate of the assay. (d) Quantitative RT-PCR for IFN-β from hMSCs after coculture with MDA (MB-231) cells. Before coculture, hMSCs were treated with siRNA for AIM2 (siAIM2 hMSCs) or IFIH1 (siIFIH1 hMSCs). Scrambled siRNA (siSCR hMSCs) were used as a control. Values are mean±S.D. for triplicate of the assay. (e) Quantitative RT-PCR assays for AIM2, IFIH1 and IFN-β in hMSCs, following coculture with Hcc38, MCF-7 and BT20 cells for 24 h. CC, hMSCs+cancer cells; CCT, hMSCs+cancer cells+TNF-α. Values are mean±S.D. for triplicate of the assay. (f) Western blot assay for TRAIL expression in BT20, Hcc38 and MCF-7 cells from control (C), TNF-α (T; 20 ng/ml) treatment or coculture with act hMSCs (MDA+hMSCs+TNF-α; CCT)
